Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 137
Filter
1.
Phys Rev Lett ; 131(12): 126901, 2023 Sep 22.
Article in English | MEDLINE | ID: mdl-37802939

ABSTRACT

We report on electron spin resonance (ESR) spectroscopy of boron-vacancy (V_{B}^{-}) centers hosted in isotopically engineered hexagonal boron nitride (hBN) crystals. We first show that isotopic purification of hBN with ^{15}N yields a simplified and well-resolved hyperfine structure of V_{B}^{-} centers, while purification with ^{10}B leads to narrower ESR linewidths. These results establish isotopically purified h^{10}B^{15}N crystals as the optimal host material for future use of V_{B}^{-} spin defects in quantum technologies. Capitalizing on these findings, we then demonstrate optically induced polarization of ^{15}N nuclei in h^{10}B^{15}N, whose mechanism relies on electron-nuclear spin mixing in the V_{B}^{-} ground state. This work opens up new prospects for future developments of spin-based quantum sensors and simulators on a two-dimensional material platform.

2.
Phys Rev Lett ; 131(11): 116902, 2023 Sep 15.
Article in English | MEDLINE | ID: mdl-37774304

ABSTRACT

Optically active spin defects in hexagonal boron nitride (hBN) are promising quantum systems for the design of two-dimensional quantum sensing units offering optimal proximity to the sample being probed. In this Letter, we first demonstrate that the electron spin resonance frequencies of boron vacancy centers (V_{B}^{-}) can be detected optically in the limit of few-atomic-layer thick hBN flakes despite the nanoscale proximity of the crystal surface that often leads to a degradation of the stability of solid-state spin defects. We then analyze the variations of the electronic spin properties of V_{B}^{-} centers with the hBN thickness with a focus on (i) the zero-field splitting parameters, (ii) the optically induced spin polarization rate and (iii) the longitudinal spin relaxation time. This Letter provides important insights into the properties of V_{B}^{-} centers embedded in ultrathin hBN flakes, which are valuable for future developments of foil-based quantum sensing technologies.

3.
Rev Sci Instrum ; 81(10): 10E102, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21033967

ABSTRACT

The first real-time detection of surface dust inside a tokamak was made using an electrostatic dust detector. A fine grid of interlocking circuit traces was installed in the NSTX vessel and biased to 50 V. Impinging dust particles created a temporary short circuit and the resulting current pulse was recorded by counting electronics. The techniques used to increase the detector sensitivity by a factor of ×10,000 to match NSTX dust levels while suppressing electrical pickup are presented. The results were validated by comparison to laboratory measurements, by the null signal from a covered detector that was only sensitive to pickup, and by the dramatic increase in signal when Li particles were introduced for wall conditioning purposes.

4.
Br J Dermatol ; 143(5): 1087-90, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11069528

ABSTRACT

Calciphylaxis is a rare, often fatal disease characterized clinically by progressive cutaneous necrosis and ulceration, and histologically by vascular calcification and thrombosis. It has been described in association with end-stage renal disease, after initiation of dialysis, following renal transplantation, and in patients with hyperparathyroidism. We present the first case of calciphylaxis occurring in a patient with both normal renal function and parathyroid hormone level and discuss the possible aetiological role of chemotherapy-induced functional protein C and protein S deficiency.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Calciphylaxis/chemically induced , Drug Eruptions/etiology , Leg Ulcer/chemically induced , Breast Neoplasms/drug therapy , Fatal Outcome , Female , Humans , Middle Aged
5.
Article in English | MEDLINE | ID: mdl-10509384

ABSTRACT

1. Polychlorinated biphenyls (PCB) were released into the environment through improper disposal for decades, causing widespread contamination. Slow biodegradation and lipophilic properties of PCB caused its persistence and concentration through food webs. Exposure to these environmental contaminants through maternal transfer during early development has been associated with neurological and endocrinological alterations in several different organisms. 2. The present study extended a preliminary investigation which suggested low level exposure to PCB altered acetylcholine biosynthesis enzyme, choline acetyltransferase (ChAT), activity in the hippocampus and basal forebrain and caused aberrations in thyroid hormone and behavior. 3. Dietary exposure of 15-day-old animals to 1.25 ppm of Aroclor 1254 (LPCB) during gestation and lactation significantly elevated ChAT activity in both areas of the brain. Animals exposed to 12.5 ppm of Aroclor 1254 (HPCB) until 15 days of age demonstrated significant elevations of ChAT activity in the basal forebrain. Thyroxine (T4) concentrations were slightly elevated in 15-day-old LPCB animals and significantly depressed in HPCB exposed pups; triiodothyronine (T3) concentrations were not altered. 4. At 30 days both LPCB and HPCB treatment groups displayed significantly depressed ChAT activity in both areas of the brain. T3 and T4 concentrations were subnormal, although T4 was not significantly depressed in LPCB animals. 5. In the Morris water maze all animals, when tested between 25 and 29 days of age, improved their latency time to the platform over 10 spatial learning trials. However, when combined means of trials 8-10 were compared, HPCB exposed animals had significantly increased latency time to the podium compared to control and LPCB animals.


Subject(s)
Aging/metabolism , Choline O-Acetyltransferase/metabolism , Environmental Pollutants/toxicity , Learning/drug effects , Memory/drug effects , Polychlorinated Biphenyls/toxicity , Prenatal Exposure Delayed Effects , Thyroid Hormones/metabolism , Animals , Animals, Newborn/physiology , Dose-Response Relationship, Drug , Eating/drug effects , Female , Hippocampus/drug effects , Hippocampus/enzymology , Maze Learning/drug effects , Pregnancy , Prosencephalon/drug effects , Prosencephalon/enzymology , Rats , Rats, Sprague-Dawley
6.
J Am Acad Dermatol ; 41(2 Pt 2): 362-4, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10426934

ABSTRACT

Lupus erythematosus profundus (LEP) is an unusual variant of cutaneous lupus erythematosus (CLE)that is characterized by chronic, recurrent inflammation of the subcutaneous tissue leading to fibrosis. It is found in the settings of both discoid and systemic lupus erythematosus. Generalized forms are extremely rare. We present a case of generalized LEP associated with genetic partial C4-deficiency.


Subject(s)
Complement C4/deficiency , Panniculitis, Lupus Erythematosus/immunology , Adult , Complement C4/genetics , Female , Humans , Lupus Erythematosus, Systemic/complications , Panniculitis, Lupus Erythematosus/complications , Panniculitis, Lupus Erythematosus/drug therapy , Panniculitis, Lupus Erythematosus/pathology , Skin/pathology
7.
Arch Intern Med ; 159(12): 1359-63, 1999 Jun 28.
Article in English | MEDLINE | ID: mdl-10386512

ABSTRACT

BACKGROUND: Symptoms of dry eye and dry mouth are common in the elderly and are often debilitating. Previous research on small populations has been inconsistent regarding the contribution to sicca symptoms of autoimmune markers, medication use, and other factors. The objective of this study was to determine the population prevalence of symptoms of dry eye and dry mouth and to evaluate possible risk factors. METHODS: This is a population-based study of 2481 individuals, aged 65 to 84 years, residing in Salisbury, Md, and identified by the Health Care Financing Medicare database. The main outcome measures included information on sicca symptoms, medical history, medication use, and joint examination results collected in a standardized manner. Autoimmune status was assessed in 1200 individuals by measuring antinuclear antibody, rheumatoid factor, and autoantibodies to the soluble nuclear antigens Ro/SS-A and La/SS-B by double immunodiffusion. RESULTS: Approximately 27% of the population reported dry eye or dry mouth symptoms to be present often or all the time and 4.4% reported both. The prevalence of dry mouth (but not dry eye) symptoms increased with age, female sex, and white race. No association of sicca symptoms was found with rheumatoid arthritis, smoking, alcohol consumption, reproductive hormonal status, or the presence of autoantibodies. A strong, dose-response relationship was observed between sicca symptoms and the use of certain medication classes. The proportion of the population prevalence of sicca symptoms attributable to the use of drying medications was estimated at 62% for dry eye and dry mouth and 38% for dry eye or dry mouth symptoms. CONCLUSIONS: Sicca symptoms are common in the elderly, and medication side effects appear to be a major underlying factor. Our results do not indicate an association between autoimmune status and sicca symptoms and do not support immunologic testing in persons with sicca symptoms in the absence of other important systemic features.


Subject(s)
Sjogren's Syndrome/etiology , Age Factors , Aged , Aged, 80 and over , Autoimmunity , Female , Humans , Male , Odds Ratio , Prevalence , Risk , Risk Factors , Saliva , Sex Factors , Sjogren's Syndrome/immunology , Tears
8.
J Neurol Neurosurg Psychiatry ; 66(4): 417-30, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10201411

ABSTRACT

As knowledge of pathophysiology grows, so does the refinement of diagnoses. Sometimes increased knowledge permits consolidation and unification. Unfortunately, at our present level of understanding, it usually demands proliferation of diagnostic categories. As tedious as this diagnostic splintering may seem, such is the price currently exacted of both the investigator and the clinician who seek to optimise management. Increased diagnostic refinement often requires inquiry into matters outside the bounds of one's specialty. Most often we turn to the radiologist or to the laboratory to narrow the differential diagnosis generated from the history and neurological examination. As we have shown, a useful intermediate step is extension of the physical examination to organs such as the skin, which are not the traditional preserve of the neurologist. That any text could confer the sophistication required for expert dermatological diagnosis is an unrealistic expectation. However, we hope that this review will encourage careful examination of the skin, hair, and nails by the neurological practitioner, with consideration of referral to a dermatologist when greater expertise is required.


Subject(s)
Nervous System Diseases/complications , Skin Diseases/complications , Cerebrovascular Disorders/complications , Humans , Melanoma/complications , Skin Diseases/diagnosis , Skin Diseases/immunology , Skin Neoplasms/complications
9.
J Rheumatol ; 26(3): 692-5, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10090184

ABSTRACT

We describe 3 patients with dermatomyositis who presented with flagellate erythema. This cutaneous eruption is characterized by erythematous linear lesions on the trunk and proximal extremities. Histologic examination of this eruption in one of our cases revealed an interface dermatitis. Review of the literature and records of 183 patients with connective tissue diseases from our institution has shown that this peculiar eruption has been reported only in dermatomyositis. Because of the location of this eruption, we encourage the use of the term "centripetal flagellate erythema" to distinguish this entity from other linear eruptions seen in patients with connective tissue diseases.


Subject(s)
Dermatomyositis/complications , Erythema/etiology , Skin/pathology , Adult , CREST Syndrome/pathology , Dermatomyositis/pathology , Diagnosis, Differential , Erythema/pathology , Female , Humans , Lupus Erythematosus, Cutaneous/pathology , Male , Middle Aged , Mixed Connective Tissue Disease/pathology , Scleroderma, Localized/pathology , Scleroderma, Systemic/pathology
10.
J Am Coll Cardiol ; 31(7): 1658-66, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9626848

ABSTRACT

OBJECTIVES: The present study describes the demographics, mortality, morbidity and recurrence rates of autoimmune-associated congenital heart block (CHB) using information from the Research Registry for Neonatal Lupus. BACKGROUND: Isolated CHB detected at or before birth is strongly associated with maternal autoantibodies to 48-kD SSB/La, 52-kD SSA/Ro and 60-kD SSA/Ro ribonucleoproteins and is a permanent manifestation of the neonatal lupus syndromes (NLS). Available data are limited by the rarity of the disease. RESULTS: The cohort includes 105 mothers whose sera contain anti-SSA/Ro or anti-SSB/La antibodies, or both, and their 113 infants diagnosed with CHB between 1970 and 1997 (56 boys, 57 girls). Of 87 pregnancies in which sufficient medical records were available, bradyarrhythmia confirmed to be CHB was initially detected before 30 weeks of gestation in 71 (82%) (median time 23 weeks). There were no cases in which major congenital cardiac anatomic defects were considered causal for the development of CHB; in 14 there were minor abnormalities. Twenty-two (19%) of the 113 children died, 16 (73%) within 3 months after birth. Cumulative probability of 3-year survival was 79%. Sixty-seven (63%) of 107 live-born children required pacemakers: 35 within 9 days of life, 15 within 1 year, and 17 after 1 year. Forty-nine of the mothers had subsequent pregnancies: 8 (16%) had another infant with CHB and 3 (6%) had a child with an isolated rash consistent with NLS. CONCLUSIONS: Data from this large series substantiate that autoantibody-associated CHB is not coincident with major structural abnormalities, is most often identified in the late second trimester, carries a substantial mortality in the neonatal period and frequently requires pacing. The recurrence rate of CHB is at least two- to three-fold higher than the rate for a mother with anti-SSA/Ro-SSB/La antibodies who never had an affected child, supporting close echocardiographic monitoring in all subsequent pregnancies, with heightened surveillance between 18 and 24 weeks of gestation.


Subject(s)
Autoimmune Diseases/congenital , Autoimmune Diseases/epidemiology , Heart Block/epidemiology , Heart Block/immunology , Autoimmune Diseases/complications , Ethnicity , Female , Gestational Age , Heart Block/complications , Heart Block/congenital , Humans , Infant, Newborn , Lupus Erythematosus, Cutaneous/complications , Male , Morbidity , Recurrence , Registries , Survival Analysis , United States/epidemiology
11.
Gynecol Oncol ; 65(2): 241-4, 1997 May.
Article in English | MEDLINE | ID: mdl-9159332

ABSTRACT

Ovarian cancer is the most overrepresented malignancy diagnosed in women with dermatomyositis. Unfortunately, screening with pelvic examination rarely detects this cancer prior to the development of metastatic disease. Our objective was to examine the use of serum CA-125 antigen levels in screening patients with dermatomyositis for ovarian cancer. A single blinded, case-control study was conducted in our institution of CA-125 levels in 14 women diagnosed with dermatomyositis between 1986 and 1993, 4 of whom subsequently developed ovarian cancer. In the 4 patients who developed ovarian cancer ("cases"), CA-125 determinations were performed on serum stored 5 to 19 months prior to the diagnosis of ovarian cancer. In the remaining 10 patients ("controls"), serum was drawn for CA-125 level determination at the time of the study, and simultaneous gynecologic and endovaginal ultrasound examinations were performed to exclude clinical evidence of ovarian cancer. All CA-125 serum measurements were performed simultaneously by a technician blinded to disease status using one diagnostic kit. CA-125 was found to be elevated in 2 patients with ovarian cancer (on serum obtained 5 and 13 months prior to the date of diagnosis of ovarian cancer) and in none of the control patients without clinical or ultrasound evidence of ovarian cancer (relative risk = 20, 95% confidence interval = [0.64, 666]). In these 14 patients, the sensitivity of CA-125 elevation for detection of ovarian cancer was 50%, and specificity was 100%. Serum CA-125 screening for ovarian cancer in patients having dermatomyositis may be useful; however, prospective studies are needed to confirm this and to determine the effect of screening on cancer stage at diagnosis and long-term survival.


Subject(s)
CA-125 Antigen/blood , Dermatomyositis/blood , Ovarian Neoplasms/blood , Ovarian Neoplasms/diagnosis , Aged , Case-Control Studies , Dermatomyositis/complications , Female , Humans , Middle Aged , Ovarian Neoplasms/complications , Sensitivity and Specificity , Single-Blind Method
12.
Lupus ; 6(2): 105-11, 1997.
Article in English | MEDLINE | ID: mdl-9061658

ABSTRACT

Unlike anti-Ro(SS-A) antibody positive subacute cutaneous lupus erythematosus (SCLE) patients, anti-Ro(SS-A) antibody positive lupus patients with Sjögren's syndrome (SS/LE) appear to have a more guarded prognosis. Our studies indicate these SS/LE patients have an increased frequency of pulmonary, neurological, and renal disease compared to SCLE patients.


Subject(s)
Autoantigens/immunology , Lupus Erythematosus, Cutaneous/immunology , RNA, Small Cytoplasmic , Ribonucleoproteins/immunology , Sjogren's Syndrome/immunology , Adolescent , Adult , Aged , Arthritis/etiology , Arthritis/immunology , Autoantibodies/blood , Central Nervous System Diseases/etiology , Central Nervous System Diseases/immunology , Female , Humans , Lung Diseases/etiology , Lung Diseases/immunology , Lupus Erythematosus, Cutaneous/complications , Middle Aged , Sjogren's Syndrome/complications , Sweet Syndrome/etiology , Sweet Syndrome/immunology , Vasculitis/etiology , Vasculitis/immunology
14.
J Am Acad Dermatol ; 35(2 Pt 1): 147-69; quiz 170-2, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8708014

ABSTRACT

The anti-Ro(SS-A) antibody is arguably the most important antibody determination except for antinuclear antibodies in evaluation of patients suspected of having lupus erythematosus. During the past 25 years, studies have established the importance of this antibody in the evaluation of patients with atypical lupus erythematosus, who have a photosensitive dermatitis as the presenting sign. The purpose of this review is to demonstrate the utility and the necessity of this antibody determination in the evaluation of all patients with cutaneous manifestations who are suspected of having a connective tissue disease.


Subject(s)
Antibodies, Antinuclear/analysis , Connective Tissue Diseases/diagnosis , Skin Diseases/diagnosis , Antibody Specificity , Connective Tissue Diseases/immunology , Humans , Lupus Erythematosus, Cutaneous/diagnosis , Lupus Erythematosus, Cutaneous/immunology , Lupus Erythematosus, Discoid/diagnosis , Lupus Erythematosus, Discoid/immunology , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Photosensitivity Disorders/diagnosis , Photosensitivity Disorders/immunology , Skin Diseases/immunology
17.
J Rheumatol ; 23(1): 101-5, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8838516

ABSTRACT

OBJECTIVE: To describe dermatomyositis (DM) sine myositis as a distinct diagnostic subclass of DM and the association with malignancy. METHODS: This case series includes all patients presenting to our primary and tertiary care outpatient dermatology department with DM and DM sine myositis between 1986 and 1993. Seven patients were diagnosed with classic DM and 12 with DM sine myositis. We analyzed average age of onset, duration of followup, clinical course, and incidence of associated malignancy in the patients with classic DM and DM sine myositis. RESULTS: No statistically significant differences were found in these 2 groups on examining age at onset and frequency of associated malignancy. Malignancy was diagnosed in 4 of 12 (25%) patients with DM sine myositis followed for a total of 50.8 patient-years (average followup 51 months) and in 2 of 7 (28%) patients with classic DM followed for a total of 20.6 patient-years (average followup 35 months). CONCLUSION: Although these patients with DM are select and few, they demonstrate that DM sine myositis may be quite similar to classic DM. It may be said that like DM, DM sine myositis may represent a paraneoplastic syndrome. DM sine myositis should be added to the currently accepted polymyositis/dermatomyositis classification system, with appropriate emphasis on the potential association with malignancy.


Subject(s)
Dermatomyositis/complications , Dermatomyositis/pathology , Myositis/complications , Myositis/pathology , Neoplasms/complications , Neoplasms/pathology , Adult , Aged , Dermatomyositis/classification , Erythema , Facial Dermatoses/pathology , Female , Hand Dermatoses/pathology , Humans , Male , Middle Aged , Paraneoplastic Syndromes/pathology , Retrospective Studies
18.
Medicine (Baltimore) ; 74(3): 109-30, 1995 May.
Article in English | MEDLINE | ID: mdl-7760718

ABSTRACT

To explore further the varied clinical expression of anti-Ro(SS-A) antibody positive patients and to determine the outcomes of these patients, we followed 100 anti-Ro(SS-A) antibody positive patients, originally seen at the Johns Hopkins Medical Institutions in 1982 and 1983, over a 10-year period. The results of this study indicate that anti-Ro(SS-A) antibody positive patients have a diverse clinical presentation and that the anti-Ro(SS-A) antibody response generally persists for years. Some of these patients appear to have a static disease process for years. However, 65% (51, including 13 deaths, of 78 patients) of the patients for whom we had follow-up data had a chronic (10 years or greater) progressive disease process. Black patients, in general, have an earlier onset of disease and may have a more severe disease than white patients. At least 25% of our anti-Ro(SS-A) antibody positive patients demonstrated a dynamic change in clinical presentation with the development of Sjögren syndrome and/or a progressive "rheumatoid-like" arthritis. Interstitial pulmonary disease, central nervous system disease, and vasculitic insults occur frequently in these patients. Renal disease occurred in 19 anti-Ro(SS-A) positive patients, and in 47% of these renal disease patients, no anti-DNA antibodies (dsDNA or ssDNA) were detected. Cutaneous manifestations are prominent in anti-Ro(SS-A) antibody positive patients with lupus. Photosensitivity and a malar dermatitis were the most common features. Twenty percent of lupus patients had discoid lesions, and 20% had SCLE lesions. Based on this study, we believe that anti-Ro(SS-A) antibody positive patients should be routinely evaluated for the emergence of systemic features. Since these systemic features are at least in part, if not solely, the result of inflammation, early treatment with steroids and/or immunosuppressive agents may minimize the damage and influence in a positive manner the significant morbidity and mortality observed in some anti-Ro(SS-A) antibody positive patients.


Subject(s)
Antibodies, Antinuclear/analysis , Autoimmune Diseases/epidemiology , Connective Tissue Diseases/epidemiology , Lupus Erythematosus, Systemic/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Connective Tissue Diseases/immunology , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Infant , Male , Middle Aged , Time Factors
20.
Medicine (Baltimore) ; 73(3): 153-60, 1994 May.
Article in English | MEDLINE | ID: mdl-8190038

ABSTRACT

A consensus regarding adequate screening to detect early malignancy in the setting of dermatomyositis (DMM) has yet to be reached. This issue is particularly relevant with regard to ovarian cancer, as early detection with routine examinations, ultrasound, and abdominal CT may not be successful. Four of 15 women diagnosed with and seen in our department for DMM between 1986 and 1993 were subsequently diagnosed with metastatic papillary serous ovarian carcinoma. One additional patient developed metastatic pelvic papillary adenocarcinoma, believed to be of ovarian origin. These diagnoses of advanced cancer were unexpected, as all women had undergone repeated cancer screenings beyond what is normally recommended for patients with DMM. The 5 women were strikingly similar in their initial presentations and subsequent courses. In each, the diagnosis of DMM was delayed from 2 to 10 months, as they were initially misdiagnosed with a photoinduced or contact dermatitis. All except 1 had severe, recalcitrant skin disease despite attempted therapy with antimalarial and immunosuppressive agents. All 4 patients who survived the postoperative period after tumor debulking showed either improvement or resolution of their DMM. It appears that women with DMM have an increased incidence of ovarian cancer, which is usually diagnosed months to a few years (range, 0 d to 6 y) after DMM has been diagnosed. Although recommendations have been made regarding cancer screening in these individuals, recommendations for initial and surveillance examinations vary from routine history and physical examination to evaluations including extensive radiologic evaluation.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Cystadenocarcinoma, Papillary/diagnosis , Dermatomyositis/diagnosis , Ovarian Neoplasms/diagnosis , Age of Onset , Aged , Antigens, Tumor-Associated, Carbohydrate/analysis , Biopsy , Cystadenocarcinoma, Papillary/complications , Cystadenocarcinoma, Papillary/surgery , Dermatomyositis/complications , Dermatomyositis/immunology , Female , Humans , Laparotomy , Middle Aged , Ovarian Neoplasms/complications , Ovarian Neoplasms/surgery , Skin Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...